Genomate for Oncologists

Navigating Complexities Together

As science advances, more genes and variants are being associated with different cancer types. This, combined with the explosion of new cancer drugs on the market, has made effectively treating your patients with cancer much more complex. You experience this firsthand with your patients.
‍
They have to deal with:
・The risk of ineffective treatments and the associated serious side effects
・The loss of precious time from taking the wrong or ineffective drugs.
・The enormous financial burden of fighting cancer

And with cancer being an opponent that continuously cheats and adapts, it falls on you to support and give them hope each time you meet.

Genomate - the world’s first AI-powered clinical decision support that matches targeted therapies to the totality of available molecular information for each patient

Empowering Oncologists: Supporting Hope

Personalized medicine

By analyzing the complex molecular profile of the cancer, Genomate can inform you of the optimal treatment for your patient - not just based on a single variant-drug association but on all the information present.

Faster
decision-making

Time to treat is critical for patients with cancer, the right drug given at the right time can make the difference between poor and positive outcomes. Genomate can quickly analyze and interpret the drug and molecular data, providing you with actionable insights to support your treatment decisions. Genomate can analyze large volumes of complex data in just 20 milliseconds, allowing for more accurate and precise molecular data processing and recommendations.

Eliminate the guesswork

By providing better personalized treatment recommendations, Genomate can eliminate the need to serially try multiple drugs on a patient to gauge their responsiveness, and can help inform you of the most effective drug the first time.

Give your patients the best chance

By selecting the most effective drug the first time, you can maximize the chance of better outcomes for your patients while reducing the cost of ineffective medications and any unnecessary side effects.

Genomate has been scientifically validated with clinical trial data and peer-reviewed by professionals around the world.

“Starting to integrate AI for treatment decisions in oncology.”

SHIVA01 was the first randomized precision oncology clinical trial. Now, with the help of DDA (Genomate technology), we can base our decisions on multiple parameters and rare alterations, making the next step toward the full implementation of the concept of precision oncology.

Prof. Christophe Le Tourneau MD PhD
Institut Curie, Paris, 2021

Nature’s Precision Oncology Journal

A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial

READ ARTICLE

Springer’s World Journal of Pediatrics

Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors

READ ARTICLE

JCO Precision Oncology - ASCO Journals

Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With MEK Mutation and PIK3CA Amplification Achieved by Dual Trametinib and Metformin Therapy

READ ARTICLE

Frequently Asked Questions